Thailand myocarditis study by Mansanguan et al.: "Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents"; Cardiovascular manifestations were found in 29.24% of patients
by Paul Alexander
Cardiovascular manifestation in adolescents after BNT162b2 mRNA COVID-19 vaccination included tachycardia, palpitation, and myopericarditis; prospective cohort study enrolled students aged 13–18 years
How long does spike protein remain in the blood? Seems at least 4 months as per Bansal and this has tremendous implications in terms of risks due to the toxic effects of the spike protein and constant immune responding and inflammation. No one knows when the cells stop making the spike protein as no one has done the studies to show when the spike ceases to exist. The issue is that the spike causes massive inflammation in your blood vessels and all your organs have vessels around them. Pathologists are constantly seeing spike protein in tissues and no nucleocapsid present indicating that the response was due to vaccine ONLY, not infection.
Where is Dr. Marion Gruber and Dr. Phil Krause when we need them?
See table 3 and I am posting again:
In 7 of 202 boys (ages 13-17 years), troponin went up and this is the key finding, do not be misdirected by the echocardiography. “Four patients had no symptoms but elevated cTnT (peak level 15.44–38.68 ng/L; normal level < 14 ng/L). The characteristics of the patients with elevated biomarkers or positive lab assessments are shown in Table 3. All patients were male and had abnormal electrocardiograms, particularly sinus tachycardia. After vaccination, ECG revealed that of the 301 patients, 247 (82.06%) had normal sinus rhythm, while an abnormal ECG finding was noted in 54 patients (17.94%) (Table 4).”
‘We enrolled 314 participants; of these, 13 participants were lost to follow-up, leaving 301 participants for analysis. The most common cardiovascular signs and symptoms were tachycardia (7.64%), shortness of breath (6.64%), palpitation (4.32%), chest pain (4.32%), and hypertension (3.99%). One participant could have more than one sign and/or symptom. Seven participants (2.33%) exhibited at least one elevated cardiac biomarker or positive lab assessments. Cardiovascular manifestations were found in 29.24% of patients, ranging from tachycardia or palpitation to myopericarditis. Myopericarditis was confirmed in one patient after vaccination. Two patients had suspected pericarditis and four patients had suspected subclinical myocarditis. In conclusion, Cardiovascular manifestation in adolescents after BNT162b2 mRNA COVID-19 vaccination included tachycardia, palpitation, and myopericarditis.’